27.11.18: Not intended for U.S. and UK Media

Bayer receives EU approval for its hemophilia A treatment Jivi®The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over timemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news